Haemonetics (HAE) Stock Forecast & Price Target

Haemonetics Corp has demonstrated strong financial performance, particularly in its plasma segment, which recorded an impressive organic growth rate of 20.2%, indicating effective market share capture amidst competitive pressures. The adjusted operating margin for the plasma business has increased by 60 basis points to a robust 36.2%, reflecting enhanced profitability across all segments. Furthermore, the company has raised its free cash flow expectations to a range of $200-220 million, signifying improved financial health and operational efficiency.

Haemonetics Corporation reported a 19.6% decline in revenue as a result of divestiture activities, highlighting the challenges the company faces in maintaining growth, particularly in its blood center segment, which is hindered by intense competition. Furthermore, the company's financial guidance for FY/26 anticipates a reported revenue decline of 1% to 4%, along with a modest expectation of organic growth of 7% to 10%, indicating a cautious outlook amid mixed performance across its product lines. Additionally, the interventional technologies sector experienced an alarming organic revenue decrease of 11.6%, suggesting underlying weaknesses in key areas that could adversely impact the company's overall growth trajectory.